INTERACT3 is a large-scale, international, multicenter, pragmatic clinical trial. There is continued uncertainty about the benefits of early reduction of intensive blood pressure (BP) in acute intraparenchymal hemorrhage (ICH), related to non-significant primary outcomes, patient selection and conflicting results from INTERACT2 and ATACH-II. INTERACT3 aims to determine the effectiveness of a set of care aimed at active management (intensive blood pressure reduction, glycemic control, treatment of pyrexia and reversal of anticoagulation) vs. usual care in HIP.